| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ... New England Journal of Medicine 354 (9), 899-910, 2006 | 4172 | 2006 |
| Multiple sclerosis–a review R Dobson, G Giovannoni European journal of neurology 26 (1), 27-40, 2019 | 2296 | 2019 |
| Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012 | 2129 | 2012 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 2100 | 2017 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 2030 | 2017 |
| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012 | 1320 | 2012 |
| A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, ... New England Journal of Medicine 362 (5), 416-426, 2010 | 1217 | 2010 |
| Meta‐analysis of early nonmotor features and risk factors for Parkinson disease AJ Noyce, JP Bestwick, L Silveira‐Moriyama, CH Hawkes, G Giovannoni, ... Annals of neurology 72 (6), 893-901, 2012 | 1131 | 2012 |
| A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution SV Ramagopalan, A Heger, AJ Berlanga, NJ Maugeri, MR Lincoln, ... Genome research 20 (10), 1352-1360, 2010 | 1121 | 2010 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1077 | 2018 |
| Multiple sclerosis: risk factors, prodromes, and potential causal pathways SV Ramagopalan, R Dobson, UC Meier, G Giovannoni The Lancet Neurology 9 (7), 727-739, 2010 | 812 | 2010 |
| A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking CE Teunissen, A Petzold, JL Bennett, FS Berven, L Brundin, M Comabella, ... Neurology 73 (22), 1914-1922, 2009 | 796 | 2009 |
| Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement MS Freedman, EJ Thompson, F Deisenhammer, G Giovannoni, ... Archives of neurology 62 (6), 865-870, 2005 | 793 | 2005 |
| The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity RB Banati, J Newcombe, RN Gunn, A Cagnin, F Turkheimer, F Heppner, ... Brain 123 (11), 2321-2337, 2000 | 783 | 2000 |
| Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies G Giovannoni, JD O'sullivan, K Turner, AJ Manson, AJL Lees Journal of Neurology, Neurosurgery & Psychiatry 68 (4), 423-428, 2000 | 764 | 2000 |
| Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases DB Clifford, A DeLuca, DM Simpson, G Arendt, G Giovannoni, A Nath The Lancet Neurology 9 (4), 438-446, 2010 | 758 | 2010 |
| Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing … E Havrdova, S Galetta, M Hutchinson, D Stefoski, D Bates, CH Polman, ... The Lancet Neurology 8 (3), 254-260, 2009 | 612 | 2009 |
| Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis CH Lu, C Macdonald-Wallis, E Gray, N Pearce, A Petzold, N Norgren, ... Neurology 84 (22), 2247-2257, 2015 | 567 | 2015 |
| The therapeutic potential of cannabis D Baker, G Pryce, G Giovannoni, AJ Thompson The Lancet Neurology 2 (5), 291-298, 2003 | 567 | 2003 |
| Brain health: time matters in multiple sclerosis G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ... Multiple sclerosis and related disorders 9, S5-S48, 2016 | 545 | 2016 |
Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)uhbs.ch의 이메일 확인됨